Is Albumin, Iodinated I 125 Serum safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Albumin, Iodinated I 125 Serum. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Information in this record refers to the use of albumin, iodinated I 125 serum (I 125 HSA) as a diagnostic agent. The International Commission on Radiological Protection states that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of I 125 HSA. This usually will result in permanent discontinuation of breastfeeding for the current infant.[1]
Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
I 125 is a low-energy pure gamma emitter with a physical half-life of 59.4 days.[1] Iodide is actively secreted into breastmilk and actively taken up by the mother's and infant's thyroid glands.
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Albumin, Iodinated I 125 Serum” (LM806). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.